HepQuant

Executive Summary

HepQuant has developed a novel, noninvasive blood-based diagnostic platform that quantitatively assesses liver function by measuring key hepatic clearance processes and blood flow. Its lead product, HepQuant DuO, provides a Disease Severity Index (DSI) that enables clinicians to accurately stage liver impairment and monitor disease progression in patients with chronic liver disease. Unlike traditional tests that rely on static biomarkers or invasive biopsies, HepQuant’s dynamic functional assay offers real-time, actionable insights to guide therapeutic decisions, potentially improving outcomes in conditions like NASH, cirrhosis, and metabolic liver disease. With a strong intellectual property portfolio and published clinical data supporting its predictive validity, the company is positioned to address a significant unmet need in hepatology.

Upcoming Catalysts (preview)

• Q3 2026Publication of pivotal clinical validation study in peer-reviewed journal70% success
• Q4 2026Strategic partnership or distribution agreement with major health system or CRO50% success
• H1 2027FDA 510(k) clearance for HepQuant DuO test60% success